Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 12/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 10/20 | 0.44 |
| ▸ | ITK | Q08881 | 2/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | KIF5B | P33176 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31523852 | 1.00 | FGFR1 (0.44) | FGFR1FGFR4ITKFGFR2FGFR3 | |
| SCHEMBL24459095 | 0.91 | RET (0.48) | FGFR1FGFR4ITKFGFR2FGFR3 | |
| SCHEMBL31523901 | 0.91 | RET (0.48) | FGFR1FGFR4ITKFGFR2FGFR3 | |
| SCHEMBL24458761 | 0.89 | FGFR1 (0.46) | FGFR1FGFR4ITKFGFR2FGFR3 | |
| SCHEMBL31524011 | 0.87 | FGFR4 (0.48) | FGFR1FGFR4ITKFGFR2FGFR3 | |
| SCHEMBL24458505 | 0.87 | FGFR4 (0.48) | FGFR1FGFR4ITKFGFR2FGFR3 | |
| SCHEMBL31523795 | 0.86 | FGFR1 (0.40) | FGFR1FGFR4FGFR2FGFR3KDR | |
| SCHEMBL24459096 | 0.86 | FGFR1 (0.40) | FGFR1FGFR4FGFR2FGFR3KDR | |
| SCHEMBL24458884 | 0.86 | ITK (0.43) | FGFR1FGFR4ITKFGFR2FGFR3 | |
| SCHEMBL31523710 | 0.86 | ITK (0.43) | FGFR1FGFR4ITKFGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022109551-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |